Pneumococcal serine-rich repeat protein (PsrP) is a putative adhesin encoded in the Streptococcus pneumoniae pathogenicity island psrP-secY2A2. Challenge of mice with serotype 4, strain TIGR4, and the isogenic mutants T4⌬psrP and T4⌬psrP-secY2A2 determined that PsrP was required for bacterial persistence in the lungs but not for colonization in the nasopharynx or replication in the bloodstream during sepsis. In vitro experiments corroborated this anatomical site-specific role; psrP mutants failed to bind to A549 and LA-4 lung cells, yet adhered normally to human nasopharyngeal epithelial cells and to cells from human and rodent capillary endothelial cell lines. We determined that the amino terminus of PsrP mediated adhesion. Microspheres coated with recombinant PsrP SRR1-BR (rPsrP SRR1-BR ) adhered to A549 cells, and moreover, preincubation of cells with rPsrP SRR1-BR inhibited TIGR4 adhesion in vitro. Antibodies against rPsrP SRR1-BR also neutralized PsrP function; antiserum against rPsrP SRR1-BR blocked TIGR4 adhesion in vitro and, following passive immunization, it protected mice against challenge. We conclude that PsrP is an adhesin required for bacterial persistence in the lungs and that rPsrP SRR1-BR is a protective antigen.
Streptococcus pneumoniae (the "pneumococcus") is a leading cause of community-acquired pneumonia, sepsis, and meningitis. The pneumococcus is primarily a commensal bacterium, and invasive pneumococcal disease (IPD) is characterized by the spread of the pneumococcus from the nasopharynx to normally sterile sites such as the lungs, blood, and brain. Young children, elderly individuals, and people who are immunocompromised are at risk for IPD. Worldwide, it is estimated that S. pneumoniae is responsible for 15 cases of IPD per 100,000 persons per year and over a million deaths annually [1, 2] . Of note, the preponderance of IPD is the result of infection with relatively few invasive clones [3] , a finding that suggests these invasive clones carry genes that facilitate disease progression and are absent in noninvasive isolates.
In 2006, it was determined that the presence of psrPsecY2A2, a 37-kb pathogenicity island, was positively correlated with the ability of S. pneumoniae to cause invasive disease [4] . Analysis of operon structure and gene content found psrP-secY2A2 to be highly homologous to loci in oral streptococci and some isolates of Staphylococcus aureus that encode a family of glycosylated proteins we now call serine-rich repeat proteins (SRRPs) [5] [6] [7] [8] [9] . SRRPs are adhesins, and they have been implicated in biofilm formation, colonization of the dental surface, and the development of infective endocarditis [6, 10 -14] . For example, Fap1, the Streptococcus sanguis SRRP, is required for biofilm formation on glass [6] . Likewise, GspB and SraP, the Streptococcus gordonii and S. aureus SRRPs, respectively, contribute to the formation of vegetative plaques on the heart valves of catheterized rats [8, 10, 15] . Thus, SRRPs serve to anchor bacteria to host surfaces.
S. pneumoniae serotype 4, strain TIGR4 contains psrP-secY2A2, which encodes an SRRP called pneumococcal serine-rich repeat protein (PsrP) [16] . PsrP is composed of 4776 aa and is one of the longest bacterial proteins known [4] . Like other SRRPs, PsrP consists of a large, cleavable signal peptide, a short serine-rich repeat region (SRR1), a basic region (BR) followed by a second extremely long serine-rich repeat area (SRR2), and a cell-wall anchor domain located at the carboxy terminus (figure 1). The SRR1 and SRR2 domain of PsrP are composed of 8 and 539 repeats, respectively, of the amino-acid sequence SAS[A/E/V]SAS[T/I]. psrP-secY2A2 also encodes 10 glycosylases and an alternate SecY2A2 translocase composed of 7 proteins. On the basis of their near-identical homology to genes in the S. gordonii GspB locus gspB-secY2A2 [4] , these genes are putatively responsible for the glycosylation and transport of PsrP [5, 10, 11, 13, [17] [18] [19] [20] [21] .
PsrP is the first SRRP to be linked to respiratory-tract disease and its disruption has been shown to attenuate TIGR4 virulence in mice [4] . In the present study, we sought to determine the role of PsrP during pneumonia. We show that PsrP is an adhesin and that its ligand is restricted to the respiratory tract. We demonstrate that PsrP mediates adhesion through its amino terminus and that antibodies against these domains inhibit pneumococcal adhesion. In addition, we determine that passive immunization with PsrP antiserum protects mice against pneumococcal challenge. We conclude that PsrP is an adhesin that facilitates bacterial persistence in the lungs and that PsrP may be a target for future vaccine design.
METHODS
Bacterial strains, media, DNA and RNA isolation. TIGR4 [16] and its mutant derivatives, T4⌬psrP and T4⌬psrP-secY2A2, were grown in Todd-Hewitt (TH) broth (Difco Laboratories) or on blood agar plates with 1 g/mL erythromycin, as needed, at 37°C in 5% CO 2 . Plasmids were maintained in Escherichia coli strain DH5␣ grown on Luria-Bertani (LB) media with 100 g/mL ampicillin. DNA and RNA were isolated by using standard protocols [22] .
Creation of T4⌬psrP-secY2A2. T4⌬psrP was previously created by insertion duplication mutagenesis [4] . To test T4⌬psrP for polar effects, Northern blot analysis was performed by using radiolabeled probes for SP1773, psrP (SP1772), and glyA (SP1771) [22] . T4⌬psrP-secY2A2 was created by allelic exchange [23] . The erythromycin resistance cassette ermB was polymerase chain reaction (PCR) amplified from plasmid pTCV-lac [24] and cloned into the TA cloning vector pCR2.1 (Invitrogen). DNA fragments representing sequences at the 5' and 3' extreme of psrP-secY2A2 (gtfB, TIGR annotation SP1757; psrP, TIGR annotation SP1772) were amplified from genomic DNA and cloned upstream and downstream of the ermB cassette in pCR2.1: gtfB F: 5'-NNNNNACTAGTGGAGATAATCAGTCT-GCTTG; gtfB R: 5'-NNNNNAAGCTTGCGCGCTCATAAGTC-GCC; psrP F: 5'-NNNNNTCTAGAGGCAAGTACATCTGCA-TCTG; psrP R: 5'-NNNNNGCGGCCGCGATAGAATATCCAG-GACG (N for the mixed nucleotide bases). The resulting mutagenic construct (ϳ3 kb) that contained the ermB cassette and the 2 flanking DNA fragments was PCR amplified and used to transform TIGR4 [25] . Deletion of the 36-kb locus was confirmed by successful amplification of a PCR product by use of primers that flanked the deleted genes, sequencing the PCR product, and failure to amplify genes previously located within psrP-secY2A2 (data not shown). We tested for polar effects by Northern blot analysis.
Characterization of the mutants. Exponential phase TIGR4, T4⌬psrP, and T4⌬psrP-secY2A2 were used to create frozen glycerol stocks. Glass tubes containing 10 mL of TH media were inoculated with these stocks to obtain an initial concentration of 10 5 cfu/mL. Microbial growth was determined by measuring the optical density of the cultures at OD 620 on an hourly basis for 8 hours. The ability to undergo autolysis was determined by addition of sodium deoxycholate (final concentration, 0.1%) to the cultures and monitoring a decline in optical density. Competence was tested for by use of published methods [25] . The presence of capsule was confirmed by Quelling reaction, by using serotype 4 -specific antiserum (Statens Serum Institute). The levels of capsule were determined by using the Stains-all Assay (Sigma) for detecting polysaccharides [26] . Polysaccharide values from T4R, an unencapsulated derivative of TIGR4 [27] , were subtracted from those of test bacteria to determine the amount of capsule present. Each experiment was performed in triplicate. Mouse experiments. Female BALB/cJ mice, 4 -5 weeks old, were obtained from the Jackson Laboratory. For all experiments, mice were anesthetized with isoflurane prior to challenge. Exponential phase cultures of S. pneumoniae were centrifuged, washed, and suspended in sterile PBS. For intranasal challenge, each mouse had 10 7 cfu of S. pneumoniae in 25 L of PBS instilled into the left nostril. Two days after the challenge, mice were sacrificed and bacterial titers in nasal lavage were determined by serial dilution of nasal elute and plating of aliquots. The number of bacteria in the lungs was assessed per gram of homogenized tissue. For intratracheal challenge, 10 5 cfu of S. pneumoniae in 100 L of PBS was placed in the throat of mice hung upright by their incisors. Aspiration of the bacteria was induced by gently pulling the tongue outward and covering the nostrils. Two days later, bacterial titers in the lungs and blood were determined. For intraperitoneal challenge, mice were injected with 10 5 cfu of S. pneumoniae in 100 L of PBS. One day after challenge, blood was collected by heart puncture.
For passive immunization experiments, 1 day before intranasal challenge 250 L of antiserum against recombinant (r)PsrP SRR1-BR , rSP0925, or naive serum from the same rabbit (see below) was intraperitoneally administered to mice. Bacterial titers in the nasopharynx, lungs, and blood were determined at day 2. For each challenge model and strain of bacteria tested, 2 replicate experiments were performed; each replciate experiment involved 4 -6 mice, for a minimum of 8 mice sampled. All experiments were performed in compliance with an approved institutional animal care and use committee protocol. Statistical analysis was performed using 1-way analysis of variance (ANOVA).
Recombinant PsrP SRR1-BR and development of antiserum. The coding region for PsrP domains SRR1-BR was PCR amplified from chromosomal DNA. The 5' primer started at the nucleotide encoding the first codon of the SRR1 domain. SRR1 F: 5'-NNNNNGAATTCTCAGCGAGTTCAACTAGTTTG. The 3' primer started at the nucleotide encoding the last amino acid of the BR. BR R: 5'-NNNNNAAGCTTTTAACTAGCACTTACTG. Primers were designed to allow directional cloning of the PCR product into the expression vector pRSET-A (Invitrogen) which added an N-terminal hexahistidine sequence to the expressed protein. Transformed E. coli strain BL21(DE3) (Novagen) was grown aerobically at 37°C in LB broth. Production of rPsrP SRR1-BR was induced by addition of isopropyl-␤-D-thiogalactoside to a concentration of 1 mmol/L when the culture had reached an OD 600 of 0.6. Six hours later, cells were harvested and the Histagged protein was purified under denaturing conditions by use of a Ni-nitrilotriacetic acid column with a QIAexpress Ni-NTA Fast Start Kit (Qiagen). Protein in the eluted fractions was made visible by Coomassie blue staining of SDS-PAGE gels loaded with fraction samples. The fraction that contained a single band corresponding to the predicted size of rPsrP SRR1-BR (45 kDa) was dialyzed extensively against PBS and stored at Ϫ20°C. Purified rPsrP SRR1-BR was sent to Invitrogen Custom Antibody and Peptide Services for creation of rabbit antiserum by use of their standard protocol. The specificity of the antiserum was confirmed by ELISA and Western blot analysis. Cloning, purification, and production of antiserum against rSP0925, an integral membrane protein, were done in the same manner described for rPsrP SRR1-BR . The primers used were as follows: SP0925 F: 5'-NNNNNGAATTCATGAAAAAACGAGC; SP0925 R: 5'-NN-NNNAAGCTTACTTCCTGAAAATAGGAGC).
Adhesion assays. Detroit 562 cells (human nasopharyngeal epithelial cells; ATCC CCL-138), A549 cells (human alveolar type II pneumocytes; ATCC CRL-185), HBMEC cells (human brain microvasculature endothelial cells; ScienCell); LA-4 cells (murine bronchial epithelial cells; ATCC CCL-196), and RB-CEC 6 cells (rat capillary endothelial cell line; provided by Elaine Tuomanen) were grown to 100% confluence on 24-well plates (ϳ10 6 cells/well). Prior to use, cells were washed with cell linespecific tissue culture media to remove serum. Cells were exposed to media that contained 10 7 cfu/mL of bacteria and incubated for 1 h at 37°C in 5% CO 2 . Nonadhering bacteria were removed by washing the cells 3 times with PBS and the number of adhering bacteria was determined by lysis of the monolayer with 0.1% Triton X-100 and plating of the lysate.
For fluorescent bead assays, rPsrP SRR1-BR or bovine serum albumin (BSA) was adsorbed to 10 8 Fluoresbrite YG 1.00-m microspheres (Polysciences), in accordance with the manufacturer's instructions. The amount of protein on each bead was calculated by subtracting the amount of protein left in the supernatant after adsorption from the amount used initially (300 g/ mL) and dividing the amount by the number of beads adsorbed. Bead assays were performed in 24-well plates with 10 7 beads/mL and 10 6 A549 cells. After 30 min of incubation, cells were washed, and attached beads were visualized and counted by using an inverted fluorescent microscope. For competitive inhibition binding assays, A549 cells were incubated with increasing concentrations of rPsrP SRR1-BR for 30 min, the cells washed, and the bacteria added to the cells. Likewise, for antibody inhibition assays, TIGR4 was incubated in tissue culture media that contained antiserum for 30 min prior to washing and use. All adhesion experiments were performed in triplicate and used a minimum of 3 wells per experiment. Statistical analysis was performed using 1-way ANOVA.
RESULTS

Deletion of psrP-secY2A2 does not affect in vitro fitness.
Northern blot analysis of psrP transcription and that of the genes immediately upstream (SP1773) and downstream (glyA) of psrP suggests that psrP has its own promoter and that its mutation does not have polar effects. Figure 2 demonstrates that expression of SP1773 and glyA are unchanged in T4⌬psrP versus TIGR4, whereas expression of psrP is abrogated. Transformation of TIGR4 with the gtfB:ermR:psrP mutagenic PCR product resulted in creation of a mutant that was deficient from gtfB to psrP-16 genes spanning Ͼ36,000 bp. Two small overlapping genes, asp4 and asp5, were left in the chromosome without their promoter to ensure that polar effects did not occur. Of note, genes downstream of asp5 are transcribed in the opposite orientation and should be unaffected. Northern blot analysis demonstrated that no upstream effects (i.e., altered SP1773 expression) occurred in T4⌬psrP-secY2A2 (figure 2). Assessment of the mutants in vitro determined that deletion of psrP or psrP-secY2A2 did not negatively affect bacterial growth in TH media, colony morphology, the presence and amount of capsular polysaccharide, autolysis, or the ability to undergo transformation (data not shown).
PsrP is required for bacterial persistence in the lungs. To determine the anatomical site-specific contribution of PsrP and to ascertain whether its accessory glycosylases and SecY2A2 transport machinery contributed to virulence, we infected mice with TIGR4, T4⌬psrP, and T4⌬psrP-secY2A2 via intranasal, intratracheal, and intraperitoneal challenge routes (figure 3). Two days after the challenge, mice that had been infected intranasally with T4⌬psrP or T4⌬psrP-secY2A2 had a number of bacteria in the nasopharynx greater than or equivalent to that of mice infected intranasally with TIGR4. Importantly, the same mice had median bacterial titers in the lungs that were 10-fold and 100-fold less, respectively, than those of mice infected with TIGR4. Intratracheal challenge of mice exacerbated the requirement for psrP or psrP-secY2A2 in vivo. Mice infected with TIGR4 had a median bacterial titer greater than 10 6 cfu/g or cfu/mL in the lungs and blood, whereas mice infected with T4⌬psrP or T4⌬psrP-secY2A2 had median bacterial titers lower than the detectable threshold (Ͻ10 3 cfu/g or cfu/mL). Intraperitoneal challenge of mice with the mutants failed to show any differences in the number of bacteria in the blood or in mortality, compared with the wild type. In all instances, mice died within 36 h (data not shown). Thus psrP-secY2A2 was not required for nasopharyngeal colonization or for replication in the blood following intraperitoneal injection. However, psrP and psrP-secY2A2 were required in the lungs, and the mutants were attenuated in their ability to progress to the blood and cause bacteremia.
psrP-secY2A2 contributes to adhesion to lungs cells, but not to adhesion to other cell types. Because SRRPs are adhesins, we tested the ability of TIGR4 and the mutants to attach to a panel of tissue culture cell lines. Adhesion assays determined that the PsrP-deficient mutants were attenuated in their ability to bind to human alveolar epithelial cells (A549) and mouse bronchial epithelial cells (LA-4). T4⌬psrP and T4⌬psrP-secY2A2 attached to A549 cells at 34% and 38% the level of TIGR4, respectively, and they attached to LA-4 cells at 40% and 21% the level of TIGR4, respectively (figure 4). In contrast, mutant bacteria adhered normally to human pharyngeal epithelial cells and to human and rodent brain microvasculature endothelial cells, findings that corroborate the observed lung-specific role for PsrP in vivo.
rPsrP SRR1-BR binds to A549 cells and competitively inhibits S. pneumoniae adhesion. SRRPs mediate adhesion through Figure 2 . Northern blot analysis showing that T4⌬psrP is an isogenic mutant. A, Northern blot analysis examining transcription of psrP (SP1772) and the genes located immediately upstream (SP1773) and downstream (glyA) of psrP in TIGR4 (T4), the mutants T4⌬psrP (⌬) and T4⌬psrP-secY2A2 (⍀), and D39, a serotype-2 strain that does not carry psrP-secy2A2. SP1773 and glyA expression were unaffected in the mutant T4⌬psrP, which suggests that psrP has its own promoter and that T4⌬psrP is an isogenic mutant. Note also that SP1773 expression is unaffected in the mutant T4⌬psrP-secY2A2, whereas psrP and glyA expression are abrogated. This is because T4⌬psrP-secY2A2 was created by allelic exchange and lacks SP1772-SP1757. Normal expression of SP1773 in T4⌬psrP-secY2A2 indicates that there were no upstream effects of the allelic exchange. B, Ethidium bromide-stained gel demonstrating that equivalent amounts of RNA were used to examine gene transcription. figure 5B and 5C ). Preincubation of A549 cells with rPsrP SRR1-BR inhibited bacterial adhesion in a dose-dependent manner ( figure 5D ). A549 cells treated with 2.5 mol/L, 0.25 mol/L, 0.025 mol/L, or 0.0025 mol/L rPsrP bound a mean of 30% Ϯ 8%, 40% Ϯ 6%, and 60% Ϯ 13%, and 103% Ϯ 2% the number of wild-type bacteria that adhered to untreated cells, respectively. These findings suggest that the amino terminus of PsrP contributes to bacterial attachment to A549 cells.
Antiserum against rPsrP SRR1-BR inhibits adhesion and protects against challenge. To further test whether SRR1-BR mediated PsrP adhesion and to determine whether antibodies against these domains inhibit bacterial adhesion, we performed a series of experiments with antiserum to rPsrP SRR1-BR , naive antiserum, and antiserum to an unrelated S. pneumoniae integral membrane protein (SP0925). Preincubation of TIGR4 with rPsrP SRR1-BR antiserum inhibited adhesion in a dose-dependent manner (figure 6). Decreased adhesion was observed at serum dilutions of 1:100, 1:500, and 1:2500, but not at 1:10,000. Naive Figure 3 . Effect of pneumococcal serine-rich repeat protein in the lungs, nasopharynx, and blood. Bacterial titers of individual 5-week-old female BALB/cJ mice infected with TIGR4, T4⌬psrP, and T4⌬psrP-secY2A2 in nasopharyngeal lavage, lungs, and blood. Mice were infected intranasally (10 7 cfu in 20 L PBS), intratracheally (10 5 cfu in 100 L PBS), and intraperitoneally (10 5 cfu in 100 L PBS). Samples were collected 48 h after intranasal challenge, 48 h after intratracheal challenge, and 24 h after intraperitoneal challenge. Horizontal bars, median value. Statistical analysis was performed using 1-way analysis of variance. Asterisks indicate a statistically significant difference, compared with values for the wild type. serum and rSP0925 antiserum had no effect on the ability of TIGR4 to adhere (1:100 dilutions). Passive immunization of mice with rPsrP SRR1-BR antiserum conferred protection against challenge with TIGR4. Mice who received rPsrP BR antiserum had approximately 100-fold fewer bacteria in the lungs and blood, compared with those who received naive or SP0925 antiserum. Passive immunization had no effect on bacterial titers in the nasopharynx (figure 7).
DISCUSSION
The finding that deletion of psrP-secY2A2 had no effect on growth rate, capsule levels, autolysis, or the ability of the mutants to undergo transformation indicated that genes in psrP-secY2A2 were not required for vital S. pneumoniae functions. This was consistent with its proposed role as a horizontally-acquired pathogenicity island. Systematic challenge of mice with T4⌬psrP and T4⌬psrP-secY2A2 by intranasal, intratracheal, and intraperitoneal routes determined that PsrP was required for bacterial persistence in the lungs, but was dispensable for colonization in the nasopharynx and for replication in the blood during sepsis. The observation that PsrP was required in the lungs was corroborated in vitro, where T4⌬psrP and T4⌬psrP-secY2A2 adhered to pneumocytes and bronchial epithelial cells at levels 21%-40% of the levels observed for the wild type, but adhered normally to It is interesting that PsrP had no effect on bacterial titers in the blood after peritoneal challenge. This separates it from other S. pneumoniae adhesins such as choline-binding protein A, which has been shown to bind to factor H [28, 29] , and choline-binding protein G, which is a protease and is required for replication to high titer in the blood [30] . The majority of S. pneumoniae adhesins have functions other than adhesion, a finding exemplified by the adhesins/enzymes 6-phosphogluconate-dehydrogenase and glutamyl tRNA synthetase [31, 32] . It is possible that PsrP has other functions that are as yet undetermined.
PsrP mutants were present at lower titers in the blood than TIGR4 after intranasal and intratracheal challenge. This occurred despite the ability of the mutants to replicate in blood following intraperitoneal injection. Most likely, the inability of the mutants to persist in the lungs resulted in fewer bacteria to disrupt the integrity of alveoli and capillary cells [33, 34] or gain access to the blood through platelet-activating factor receptormediated endocytosis [35] . Previously, we demonstrated that 66% of mice challenged with T4⌬psrP survived intranasal challenge, whereas only 8% challenged with TIGR4 survived [4] . Consistent with the inability of other S. pneumoniae mutants deficient in lung-required virulence factors [36] , it seems that impeding the development of pneumonia protects mice against disseminated infection and death.
SRRPs mediate attachment through the BR [6, 10 -14] . The adhesion of latex beads coated with rPsrP SRR1-BR to cells, competitive inhibition of TIGR4 with rPsrP SRR1-BR , and inhibition of cell binding by antiserum against rPsrP SRR1-BR, suggests that the BR of PsrP does the same, although the SRR1 domain remains to be excluded. One important consideration is that TIGR4 is encapsulated, and that capsule inhibits S. pneumoniae adhesion [37] . The finding that the amino terminus of PsrP contributes to adhesion suggests that the extremely long SRR2 domain serves to extend the SRR1-BR domains beyond the capsule such that the pneumococcus can adhere to cells while remaining protected from phagocytes. Future experiments will test this hypothetical model.
Antibodies against rPsrP SRR1-BR inhibited the ability of TIGR4 to adhere to A549 cells in vitro and reduced the number of bacteria in the lungs and blood of challenged mice. Mechanisms for antibody mediated protection most likely included neutralization of the PsrP binding domain, such as that which was observed in vitro, and potentially, opsonization of the pneumococcus. The latter is possible if the SRR1 and BR domain are extended beyond the capsule barrier. Currently, we are performing experiments to determine whether active intramuscular vaccination with rPsrP is protective and whether mucosal delivery (i.e., development of anti-PsrP IgA in the lungs) confers protection as well.
Unexpectedly, it was observed that mutants deficient in PsrP colonized the nasopharynx better than TIGR4. Because differences in growth rate and capsule levels were not observed in vitro, we speculate that production of PsrP is metabolically costly. PsrP is putatively glycosylated and is composed primarily Figure 7 . Passive immunization of mice with rabbit antiserum against rPsrP SRR1-BR protects mice against pneumococcal challenge. Bacterial titers of individual 5 week old female Balb/cJ mice infected intranasally with TIGR4 (10 7 cfu) following passive immunization with 250 L of naive or high-titer antiserum against rPsrP SRR1-BR and antiserum against rSP0925. Antiserum was delivered by intraperitoneal injection, one day prior to challenge. Horizontal bars indicate median value. Statistical analysis was performed using a 1-way analysis of variance.
of the amino acids serine (2236 [46%] of 4776 aa) and alanine (1526 [32%] of 4776 aa). Production of PsrP in the nutrientlimited environment of the nasopharynx may deplete energy and amino acid stores. In support of this possibility, we have determined that PsrP production is reduced to 10% of normal levels during growth in 20% TH media and that PsrP production is fully restored by the addition of sucrose (data not shown).
In all experiments, T4⌬psrP and T4⌬psrP-secY2A2 behaved similarly. This suggests that the glycosyltransferases and alternate Sec translocase do not make an additional contribution to S. pneumoniae virulence independent of PsrP. One important caveat is that we did not include a complemented mutant in these studies (T4⌬psrP expressing psrP) . Because of the large size of psrP (14,331 bp) and the high number of nucleotide repeats encoding the SRR2 domain, we have been unable to amplify fulllength psrP or clone large fragments of psrP without DNA rearrangement. Thus, despite that Northern blot analyses indicating that T4⌬psrP has no polar effects, caution is warranted when attributing the attenuated phenotype solely to psrP.
In summary, we have determined that PsrP is an S. pneumoniae adhesin that it is required for adhesion in vitro and for persistence in the lower respiratory tract. Our studies have demonstrated that PsrP adhesion is mediated by the amino terminus of the protein and, moreover, antibodies against the SRR1 and BR domain inhibit S. pneumoniae adhesion and protect mice against pneumococcal challenge. Future studies will focus on identifying the ligand for PsrP in the lungs and determining whether active vaccination confers protective immunity.
